We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bimodal Endoscope Detects Early Signs of Esophageal Cancer

By HospiMedica International staff writers
Posted on 21 Sep 2016
A near-infrared (NIR) fluorescence and visible light endoscope can aid in the detection of early esophageal malignancy such as in Barrett's esophagus (BE), according to a new study.

Developed at the University of Cambridge (Cambridge; United Kingdom), the bimodal (NIR and white light) endoscope detects fluorescent wheat germ agglutinin (WGA-IR800CW) dyes in order to construct a clinically translatable image. More...
The endoscope works by co-registering the NIR and white light images, and then removing the honeycomb artifact arising from the fiberoptic bundle. The resulting images provide a field of view of 63o and an image resolution of 182X182 μm.

The researchers successfully demonstrated (ex vivo) that the system can distinguish between gastric and squamous tissue types in mouse stomachs, and accurately detect WGA-IR800CW fluorescence in human esophageal resections. According to the researchers, the new endoscope can moreaccurately delineate dysplasia and help to overcome tissue auto-fluorescence, which limits both sensitivity and contrast of fluorescently labeled lectins under visible light. The study was published on August 4, 2016, in Journal of Biomedical Optics.

“People who are at a high risk of developing esophageal cancer, such as those with Barrett's esophagus, could be closely monitored with this technique, and removing patches of pre-cancerous cells could prevent some cases of esophageal cancer,” said senior author Sarah Bohndiek, PhD, of the Cambridge Cancer Research Institute. “But we need to do some further testing before clinical trials with patients can be set up to see how effective the approach could be at saving lives.”

Barrett’s Esophagus develops as a result of chronic injury from gastroesophageal reflux disease (GERD), which causes metaplasia of the normal squamous epithelium lining of the esophagus, replacing them with goblet cells, which are usually found lower in the gastrointestinal (GI) tract. The significance of BE is its strong association with esophageal adenocarcinoma, a particularly lethal form of cancer.

Related Links:
University of Cambridge


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Pediatric Mask
Respire SOFT
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.